2022
Rebleeding in peptic ulcer bleeding – a nationwide cohort study of 19,537 patients
Laursen S, Stanley A, Laine L, de Muckadell O. Rebleeding in peptic ulcer bleeding – a nationwide cohort study of 19,537 patients. Scandinavian Journal Of Gastroenterology 2022, 57: 1423-1429. PMID: 35853234, DOI: 10.1080/00365521.2022.2098050.Peer-Reviewed Original ResearchConceptsPeptic ulcer bleedingNationwide cohort studyUlcer bleedingHemodynamic instabilityCohort studyDuodenal ulcerHigh-risk endoscopic stigmataNon-ulcer lesionsHigh-risk stigmataLogistic regression analysisEndoscopic stigmataPersistent bleedingEndoscopic therapyFrequent complicationConsecutive patientsSuch patientsPrognostic consequencesHigh riskPatientsInterventional radiologyBleedingTwo-fold increaseMortalityUlcersStrongest predictor
2004
Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis
Ofman JJ, Badamgarav E, Henning JM, Knight K, Laine L. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis. The American Journal Of Medicine 2004, 116: 835-842. PMID: 15178499, DOI: 10.1016/j.amjmed.2004.02.028.Peer-Reviewed Original ResearchConceptsCOX-2 inhibitorsCardiac eventsHealth care costsGastrointestinal bleedingTraditional NSAIDsHigh riskGreater total health care costsNonsteroidal anti-inflammatory drug therapyCare costsAnti-inflammatory drug therapyCOX-2 inhibitor therapyTotal health care costsCyclooxygenase-2 selective inhibitorNonsteroidal anti-inflammatory drugsCardiac risk profileProton pump inhibitorsAnti-inflammatory drugsLogistic regression analysisNSAID therapyNSAID usersGastrointestinal riskInhibitor useNonselective NSAIDsInhibitor therapyCardiac risk